AccelLAB a preclinical contract research organization offering implant safety and performance evaluation to the medical device industry, announces that it is inaugurating its latest histology service center with 3800 additional sq. ft. of new infrastructures and equipment. By doing so, the preclinical research center significantly expands and upgrades its medical device evaluation service offer with state-of-the-art laboratories including on-site non-decalcified histology embedding/processing centers equipped with two (2) Exakt microgrinding/micropolishing equipment, as well as two (2) Micro Computed Tomography equipment (Nikon XTH 225 and a brand-new Bruker SkyScan 1272 Micro CT). This will be operated under full GLP compliance with highly qualified on-site technical and pathology staff.
“Scaling up our histopathology service offer by doubling our original histology lab space marks another important milestone reached in our 15-year history,” says Dr. Guy Leclerc, President and CEO. “This expansion will resume in 2019 with major infrastructural changes including additional vivarium suites and operating rooms, which will be implemented later this year”. This reflects AccelLAB’s commitment to remain at the top of preclinical and translational research while accelerating device and biologics development programs for a faster access to market with its turn-key services it is recognized for, while meeting the highest industry standard of quality, health, and research practices.
Celebrating its 15th anniversary in 2019, AccelLAB Inc., a Citoxlab Company, is a preclinical CRO dedicated to the medical device, biologics and biotechnology industries. With 40000 ft2 facilities, its translational research center provides in life services to conduct high-quality product safety, efficacy and performance studies from the proof of concept to regulatory submission in a strict GLP environment. Preclinical evaluation services include study design, on-site surgeries/interventions, histology, histomorphometry, histopathology and clinical pathology. On-site sophisticated imaging modalities include magnetic resonance imaging (MRI), whole-body computer tomography (CT), high-definition radiography (Faxitron), optical coherence tomography (OCT), and micro-computed tomography (Micro CT). Full histopathological analyses and quantitative study reports are provided by experienced study directors and veterinary pathologists. Fully AAALAC and CCAC-certified, AccelLAB has also been audited by the FDA.
About Citoxlab Group :
With nine facilities located in France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas City), Denmark (Copenhagen) and Hungary (Veszprém, Budapest, Szeged), Citoxlab Group offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. Citoxlab and Atlanbio also offer both preclinical and clinical bioanalysis and biomarker services. AccelLAB provides efficacy and safety studies of medical devices (cardiology, ENT, orthopedics and regenerative medicine). In partnership with Stemina (Madison, USA) the Group offers screening services using human embryonic stem cell models. With the recently acquired Solvo Biotechnology, products and services in the field of transporters and DDI are now available. Today, Citoxlab has 1,400 employees working at nine sites with state-of-the-art facilities, generating revenues of €150M ($175M). The company has a world-class top-level management team in scientific, financial and business activities. www.citoxlab.com